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The ST2 receptor is a member of the Toll/IL-1R superfamily and interleukin-33 (IL-33) 
is its agonist. Recently, it has been demonstrated that IL-33/ST2 axis plays key roles in 
inflammation and immune mediated diseases. Here, we investigated the effect of ST2 
deficiency in Staphylococcus aureus-induced septic arthritis physiopathology. Synovial 
fluid samples from septic arthritis and osteoarthritis individuals were assessed regarding 
IL-33 and soluble (s) ST2 levels. The IL-33 levels in samples from synovial fluid were 
significantly increased, whereas no sST2 levels were detected in patients with septic 
arthritis when compared with osteoarthritis individuals. The intra-articular injection of 
1 × 107 colony-forming unity/10 μl of S. aureus American Type Culture Collection 6538 
in wild-type (WT) mice induced IL-33 and sST2 production with a profile resembling the 
observation in the synovial fluid of septic arthritis patients. Data using WT, and ST2 defi-
cient (−/−) and interferon-γ (IFN-γ)−/− mice showed that ST2 deficiency shifts the immune 
balance toward a type 1 immune response that contributes to eliminating the infection 
due to enhanced microbicide effect via NO production by neutrophils and macrophages. 
In fact, the treatment of ST2−/− bone marrow-derived macrophage cells with anti-IFN-γ 
abrogates the beneficial phenotype in the absence of ST2, which confirms that ST2 
deficiency leads to IFN-γ expression and boosts the bacterial killing activity of macro-
phages against S. aureus. In agreement, WT cells achieved similar immune response to 
ST2 deficiency by IFN-γ treatment. The present results unveil a previously unrecognized 
beneficial effect of ST2 deficiency in S. aureus-induced septic arthritis.
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inTrODUcTiOn
Interleukin-33 (IL-33) is a member of the IL-1 cytokine family 
that can act either as a chromatin-associated nuclear factor or as a 
classic cytokine (1, 2). Once released, IL-33 binds to the heterodi-
meric receptor complex consisting of ST2 and IL-1 receptor acces-
sory protein recruiting typical intracellular proteins of the toll-like 
receptor (TLR)/IL-1 superfamily (3, 4). The transmembrane form 
of ST2, encoded by the ST2 gene is expressed by cells including 
activated Th2 cells (5), mast cells (6), and ILC2 (7). ST2 is alter-
natively spliced to produce a soluble form (sST2), which acts as 
an IL-33 scavenger (8). Antibodies targeting ST2, ST2-Fc fusion 
proteins or ST2 deficient mice contributed to demonstrate that the 
lack of IL-33/ST2 signaling favors the expansion of Th1 cells and 
inhibits Th2 cell-mediated immune responses (5, 8–11).
Conversely, IL-33/ST2 signaling has now emerging pleiotropic 
properties, including type 1 and 3 immunity and regulatory 
 patterns (4, 12). Indeed, IL-33/ST2 has a proinflammatory role 
in Th1 and Th17 immune responses (13, 14). Both, IL-33 and 
ST2 are expressed in the human and mouse model of rheumatoid 
arthritis (RA) synovial tissue, are elevated in the sera and synovial 
fluids of RA patients and manifest correlation with disease pro-
gression (14–18). Endothelial cells and fibroblasts constitutively 
express high levels of IL-33 mRNA and protein, indicating that 
they are a key source of IL-33 in the inflamed synovium (11, 16). 
Thus, IL-33 and ST2 are expressed by joint cells in inflammatory 
conditions.
During infections, IL-33/ST2 signaling plays dual roles 
depending on the organ involved and the Th1/Th2 shifting neces-
sary to better control the infectious foci (4). IL-33 is protective 
during acute phase of sepsis (19), keratitis caused by Pseudomonas 
aeruginosa (20) or Staphylococcus aureus wound infection (21) 
and in parasitic diseases with Trichuris muris (22), Schistosoma 
mansoni (23), or Toxoplasma gondii (24), whereas it is deleteri-
ous during cutaneous and visceral leishmaniasis (10, 25, 26). 
Thus, strategies targeting IL-33/ST2 pathway should account the 
cytokine milieu and disease context.
Septic arthritis is considered as one of the most aggressive 
joint diseases due to its rapidly progressive disease profile, pain, 
severe joint lesion, and dysfunction even with therapy onset 
(27, 28). Patients with underlying joint diseases, such as RA are 
4- to 15-fold more susceptible to septic arthritis than general 
population (29). Joint lesions facilitate bacterial colonization 
together with a reduced immune response due to chronic treat-
ment with disease modifying drugs, corticosteroids and biologic 
therapies that cause patient immune suppression (30–32). 
S. aureus is the most common cause of SA (31). There is evidence 
that both drug resistant S. aureus such as methicillin-resistant 
S. aureus and non-drug resistant S. aureus cause septic arthritis 
(28, 29, 33, 34). The fast development of joint destruction in septic 
arthritis supports the urgent need for development of new treat-
ment strategies against S. aureus arthritis.
As IL-33 and its receptor ST2 have been recognized as an 
important axis in joint inflammation and infectious diseases, we 
therefore, investigated whether ST2 deficiency would influence 
the outcome and contributing mechanisms of this receptor in 
S. aureus-induced septic arthritis.
MaTerials anD MeThODs
animals
Male BALB/c [wild-type (WT)], ST2−/− (BALB/c background), 
C57BL/6 (WT), and interferon-γ (IFN-γ)−/− (C57BL/6 background) 
mice were used in this study. ST2−/− mice were originally obtained 
from Dr. Andrew McKenzie (LMB, Cambridge) (15). IFN-γ−/− mice 
were obtained from Jackson Laboratories (Bar Harbor, ME, USA).
A total of 1,360 mice were used in this study. All mice were 
housed in standard clear plastic cages with free access to water 
and food, and temperature of 23°C ±  2 at constant humidity. 
A  12/12  h light/dark cycle was used with lights on at 6 a.m. 
and off at 6 p.m. The behavioral tests were performed between 
9 a.m. and 5 p.m. in a temperature-controlled room (23°C ± 2). 
Animal care and handling procedures were in accordance with 
the International Association for Study of Pain guidelines, and all 
protocols were approved by the Ethics Committee of the Londrina 
State University (OF.CIRC.CEUA, process number 20165/2009).
clinical samples
Synovial fluid samples from 4 to 5 individuals with septic arthritis 
and 10 osteoarthritis individuals were collected in order to assess 
IL-33, sST2, and IFN-γ levels using ELISA kits (R&D Systems, 
Minneapolis, MN, USA). All individuals were recruited at the 
Division of Rheumatology, Hospital das Clínicas, Ribeirão 
Preto Medical School (HC-FMRP), São Paulo, Brazil, and were 
informed about the aims of the study and provided written con-
sent before participating. The Human Ethics Committee of the 
FMRP approved this study (Process number 4971/2012).
Mouse Model of S. aureus-induced 
arthritis
Staphylococcus aureus was obtained from American Type Culture 
Collection (ATCC, USA) number 6538. Septic arthritis was 
induced by local injection of 107 colony-forming unity (CFU) of 
S. aureus in 10 µl in sterile PBS into the right knee joints. Intra-
articular (i.a.) injection of 10 µl of sterile saline was used as negative 
control group. To assess the intensity of arthritis, a clinical score 
was carried out using macroscopic inspection of the knee joints 
yielding a score of 0–4 for each limb (0—normal, 1—periarticular 
erythema, 2—articular erythema and edema, 3—function loss 
with difficult locomotion and articular extension, 4—purulent 
process with abscess formation) (28).
assessment of articular hyperalgesia
Articular mechanical hyperalgesia was assessed over 27  days 
post-i.a. infection with S. aureus using an electronic pressure 
meter (IITC 152 Inc., Life Science Instruments California, CA, 
USA) (35). The electronic pressure-meter apparatus automati-
cally recorded the intensity of the force applied when the paw was 
withdrawn. The results were expressed as the flexion-elicited 
withdrawal threshold in grams.
Determination of Knee Joint edema
Knee joint edema was assessed over 27 days post-i.a. infection 
with S. aureus using a digital caliper (Digmatic Caliper, Mitutoyo 
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Corp., Kanagawa, Japan). The results were expressed as the differ-
ence (delta, Δ) between the diameter measured before (basal) and 
after induction of articular infection in millimeter.
Quantification of cytokines
Knee joints were dissected out and frozen with liquid nitrogen. 
Then, samples were homogenized in a buffer containing a 
cocktail of protease inhibitors [NaCl 0.4  M, Tween 20 0.05%, 
bovine albumin 0.5%, phenyl methyl sulphonyl fluoride 0.1 mM, 
benzethonium chloride 0.1  mM, EDTA 10  mM, aprotinin 
20 KI·ml−1 (0.01 mg·ml−1) diluted in phosphate buffer saline pH 
7.4], centrifuged and the supernatants were used to determine the 
levels of sST2, IL-33, TNF-α, IL-1β, IFN-γ, IL-4, IL-5, IL-17, and 
IL-10. The results were expressed as picogram per 100 mg of tis-
sue (36). Supernatants from bone marrow-derived macrophages 
(BMDMs) culture were also collected to determine the levels of 
IL-33 and IFN-γ and the results were expressed as picogram/mil-
liliter. All measurements were performed using ELISA kits from 
R&D Systems (Minneapolis, MN, USA) or eBioscience (San Siego, 
CA, USA). The minimum sensitivity of the kits was ≥0.7 pg/ml.
Determination of Joint leukocyte 
infiltration and Bacterial counts
Knee joints cavities were exposed and washed with the aid of a 
pipette three times with a total volume of 10 µl of sterile saline 
plus 1 mM EDTA. Each washing procedure used approximately 
3.3 µl of saline. The total number of leukocytes was determined 
in a Neubauer chamber diluted in Turk’s solution and differential 
cell counts were performed in Rosenfeld stained slices using a 
light microscope. The results were expressed as the number 
of total of leukocytes, neutrophils, or mononuclear cells × 104 
(mean ± SEM)/per cavity. The same samples were plated on blood 
agar to determine the bacterial load in the joints and the results 
were expressed as CFU per cavity. Additionally, spleen from 
the same animals were explanted and plated on blood agar to 
determine the bacterial load. The results were expressed as CFU 
per spleen.
histological analysis
Whole knee joints were removed and fixed in 4% formaldehyde 
for 2 days before decalcification in 5% formic acid and processing 
for paraffin embedding. Tissue sections (5 µm) were stained with 
hematoxylin and eosin. All the slides were coded and assessed 
in a blinded manner by two observers regarding the degree of 
synovitis (leukocyte infiltration score) and cartilage destruction.
Proteoglycan Quantification assay
Chondroitin sulfate from patella samples was quantitated using 
1,9-dimethyl-methylene blue assay. The glycosaminoglycan 
content of samples was calculated from the standard curve of 
chondroitin sulfate (14).
rT-qPcr
Total RNA was extracted from 1 × 106 S. aureus-infected BMDMs 
[multiplicity of infection (MOI): 3] and from whole knee joint 
samples using TRIzol reagent (Invitrogen). For RT-qPCR, the 
total RNA was extracted with SV Total RNA Isolation System 
Kit (Promega, USA) according to the manufacturer’s instruc-
tions. RT-PCR and qPCR were performed using GoTaq® 2-Step 
RT-qPCR System (Promega) on a StepOnePlus™Real-Time PCR 
System (Applied Biosystems®) using primers for Rankl, Rank, 
Opg, IFN-γ, iNOS, IL-33, and ST2. Raw data were normalized to 
Gadph expression and were analyzed by the 2−(ΔΔCt) method.
Western Blot
A total of 2 × 106 BMDMs were seeded per well and pretreated 
with IFN-γ (100 U/ml, Invitrogen), anti-IFN-γ (10 µg/ml, R&D 
Systems), or medium for 1 h followed by infection with S. aureus 
(MOI = 3) for 18 h. The supernatants were collected to further 
assess the nitrite production. The cell lysates were collected using 
RIPA buffer containing CST—Protease/Phosphatase Inhibitor 
Cocktail (Cell Signaling, USA). Whole knee joint samples using 
RIPA buffer containing Protease/Phosphatase Inhibitor Cocktail 
(Cell Signaling, USA) were also collected. Total protein from 
cells and knee joint samples were quantified and the lysates 
were mixed with 4× Laemmli sample buffer (Sigma-Aldrich). 
Antibody against iNOS (1:10,000, Sigma Chemical Co., St. Louis, 
MO, USA) was used for protein detection after electrophoresis in 
10% SDS-PAGE gel, transference into nitrocellulose membrane 
(Merck Millipore, USA), and blocking. HRP-conjugated sec-
ondary antibody was used (KPL, USA). Immunodetection was 
performed using an enhanced chemiluminescence technique 
(ChemiDoc XRS System, Biorad Laboratories). The membrane 
was stripped and reprobed with β-actin (1:5,000, Sigma Chemical 
Co., St. Louis, MO, USA) as a loading control. Densitometry data 
were measured after normalization to the control (house-keeping 
gene, β-actin) using Scientific Imaging Systems (Image Lab 3.0 
software; Biorad Laboratories, Hercules, CA, USA). Full scan 
of the original uncropped western blot is shown in Figure S4 in 
Supplementary Material.
FiTc-labeling of staphylococci
Staphylococcus aureus ATCC 6538 was grown to mid-log phase 
in fresh Muller–Hinton broth. Bacteria were washed twice with 
sterile PBS and labeled in 0.1 mg/ml FITC (Sigma Chemical Co., 
St. Louis, MO, USA) for 1 h at 37°C with shaking. Prior to use, 
bacteria were washed twice with PBS and re-suspended in Hank’s 
solution (Sigma Chemical Co., St. Louis, MO, USA).
Flow cytometry analysis
Phagocytosis assay and detection of intracellular cytokines was 
performed using an FACS Verse (BD Biosciences, San Diego, 
CA, USA) flow cytometer. Phagocytosis of naïve BMDMs and 
naïve neutrophils was measured using FITC-labeled S. aureus as 
previously described in Ref. (37). In other set of experiments to 
assess the intracellular cytokines, draining popliteal lymph nodes 
(LNs) were collected from naïve and infected mice at indicated 
times post-infection and processed as a pool. Cell suspensions 
obtained (1 × 106 cells) were stained with fluorochrome-conju-
gated antibodies for CD4 (H129.19), IFN-γ (B27), IL-4 (11B11), 
IL-17 (TC11-18H10), or IL-10 (JES5-16E3) from BD Biosciences 
(San Diego, CA, USA). Data were analyzed with FlowJo software 
(TreeStar, Ashland, OR, USA).
FigUre 1 | Interleukin-33 (IL-33) and sST2 levels in synovial fluid samples of septic arthritis and osteoarthritis patients, and similar profile in mouse septic arthritis. 
(a,B) Synovial fluid samples from patients with septic arthritis and osteoarthritis were collected and processed to determine the levels of IL-33 and sST2 by ELISA. 
(c,D) Staphylococcus aureus or saline (day 0) was injected in in the femur-tibial joint of wild-type and knee joints samples were collected and processed to determine 
the levels of IL-33 and sST2 at indicated points (7–28 days) post S. aureus injection by ELISA. For clinical samples analysis: n = 5 for septic arthritis and n = 10 for 
osteoarthritis patients. *P < 0.05 vs osteoarthritic patients group (a,B). Kruskal–Wallis test followed by Dunn’s test. For mice samples analysis: n = 6 per group, 
representative of two independent experiments. *P < 0.05 vs day 0 of infection (c,D). Two-tailed unpaired Student’s t-test.
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Killing assay
To obtain macrophages (BMDM), cells were differentiated during 
6 days in RPMI medium plus 20% supernatant from L929 cells 
(38). To obtain neutrophils, cells were isolated by Percoll gradient 
(39). BMDM or neutrophils (1 × 106/well) were then pretreated 
with IFN-γ (100 U/ml), anti-IFN-γ (10 µg/ml), or medium for 
1 h followed by infection with S. aureus (MOI = 3). Other wells 
with only bacteria and RPMI medium were prepared as a posi-
tive control. The plates were centrifuged for 3 min at 5,000 rpm 
and returned to the cell incubator for 3 h. The supernatants were 
collected to further assess the nitrite production. Cells were then 
lysed by addition of Triton X-100 0.2%. The lysates were serially 
diluted 1:100,000 in 1 × PBS and plated on blood agar plates and 
incubated overnight at 37°C. The results were expressed as % of 
viable bacteria by comparing with the positive control.
nitrite Determination
Nitrite (NO2−) accumulation, as an indication of NO produc-
tion was measured using Griess reagent. In this assay, 0.1 ml of 
sample was mixed with 0.1 ml of Griess reagent in a multiwell 
plate, and the absorbance was read at 550 nm 10 min later. Nitrite 
concentrations were determined by reference to a standard curve 
of sodium nitrite (1–200 µmol/l) (40).
Pharmacological Treatment of Mice
In some experiments, infected WT and ST2−/− were treated intra-
peritoneally with 30  mg/kg of aminoguanidine (AMG; Sigma, 
Chemical Co., St. Louis, MO, USA), a selective iNOS inhibitor, 
for 28 consecutive days (once a day). Mice were euthanized at 
the 28th day post-infection, and inflammatory parameters and 
bacterial load in joint and spleen tissues were analyzed.
culture of Macrophages like-cells
Peritoneal cells from naïve and infected mice were cultured in 
RPMI medium for 4 h to allow macrophages to adhere. The float-
ing cells were washed away and the adherent macrophages were 
challenged with lipoteichoic acid (LTA, 10 µg/ml), a TLR2 agonist 
plus IFN-γ (100 U/ml) in RPMI for 24 h at 37°C. The supernatants 
were harvested to assess the NO2− accumulation.
statistical analysis
Statistical significance was analyzed using PRISM 6.01 (GraphPad 
Software, USA). The data are expressed as the mean ±  SEM. 
Statistical differences were considered when P < 0.05.
resUlTs
il-33 and ssT2 levels in synovial Fluids 
of septic arthritis and Osteoarthritis 
Patients, and a similar Profile in 
Mouse septic arthritis
First, the IL-33 and sST2 levels in the synovial fluid of patients 
with septic arthritis and osteoarthritis were determined. Clinical 
and demographic characteristics of these patients are presented as 
Table S1 in Supplementary Material. IL-33 levels were higher in the 
synovial fluid of SA patients than in the synovial fluid OA patients 
(Figure 1A). The levels of sST2 were below limit detection in septic 
arthritis patients (Figure 1B). These clinical results indicate that 
there are higher levels of IL-33 in septic arthritis primary foci than 
in osteoarthritis. In mice, the i.a. injection of S. aureus induced the 
increase of IL-33 levels (Figure 1C) and decreased of sST2 levels 
(Figure 1D) in the knee joints that lasted for 28 days compared 
with day 0 (representative group that received only saline). Despite 
the detection of IL-33 in the synovial fluid and knee joints of septic 
arthritis patients and mice, respectively, whether IL-33 and its 
receptor ST2 have a function in disease is unknown.
sT2 receptor Deficiency ameliorates  
S. aureus-induced septic arthritis
Considering that septic arthritis triggered the production of 
IL-33 and reduction of sST2 levels in the synovial fluid of patients 
FigUre 2 | ST2 deficiency ameliorates Staphylococcus aureus-induced septic arthritis. S. aureus or saline was injected in the femur-tibial joint of wild-type (WT) 
and ST2−/− mice. (a) Mechanical hyperalgesia, (B) articular edema, and (c) clinical score were evaluated over 27 days post-infection. Knee joints were collected  
and processed to determine the levels of (D) TNF-α and (e) IL-1β by ELISA determined at days 7–28 days post-infection. (F) Total leukocytes, (g) neutrophil, and 
(h) mononuclear recruitment to the knee joint were determined at 7–28 days post-infection. Knee joint samples were collected at the 28th day post-infection for 
histological analysis by hematoxylin/eosin stained slices to determine: (i) synovitis score (intensity: 1–4) and (J) cartilage destruction score (intensity: 1–4).  
(K) Representative images of knee joints at 28 post-infection in original magnification ×10. The letter a indicates a heavily inflamed joint with cartilage destruction 
and pannus formation. (F) Proteoglycan content in patella determined at 7–28 days post-infection. For inflammatory parameters and proteoglycan content: n = 6 
per group per in vivo experiment, representative of two independent experiments. *P < 0.05 vs naïve mice group, #P < 0.05 vs WT mice group (a–h,l). One-way 
ANOVA followed by Tukey’s test. For histological analysis: n = 8 per group per experiment, representative of two independent experiments. *P < 0.05 vs naïve 
mice group, #P < 0.05 vs WT mice group (i–K). Kruskal–Wallis test followed by Dunn’s test. Abbreviations: C, cartilage; JC, joint cavity.
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(Figure 1A), we used a model of S. aureus-induced septic arthritis 
in WT (balb/c) and ST2−/− mice to investigate the disease out-
come in the ST2 deficiency scenario. i.a. injection of S. aureus 
increased mechanical hyperalgesia in WT mice as observed by 
reduction in the mechanical threshold when compared with 
naïve mice (Figure  2A). Interestingly, the S. aureus-induced 
hyperalgesia was similar between WT and ST2−/− mice up to 
9 days of infection. However, from 11 days onward, S. aureus-
induced hyperalgesia started to reduce in ST2−/− compared with 
WT mice. This result may have, at least, two explanations; ST2 −/− 
mice respond better than WT against S. aureus infection or by 
lacking ST2, these mice would present a reduction of hyperalgesia 
since IL-33 is a hyperalgesic cytokine (13). Moreover, IL-33 also 
mediates the paw edema induced by carrageenan (41). Indeed, 
WT mice presented increased edema when compared with 
ST2−/− mice (Figure  2B). The reduction of hyperalgesia and 
edema in ST2−/− mice was followed by lower clinical score as well 
(Figure  2C). WT mice also showed increased levels of TNF-α 
and IL-1β after infection (Figures  2D,E, respectively), inflam-
matory cell recruitment to the knee joint (Figures 2F–H), and 
tissue inflammatory cell infiltration demonstrated histologically 
(Figures  2I,K) when compared with ST2−/− mice. Ultimately, 
these features resulted in increased cartilage destruction with 
only parts of cartilage remaining (Figures  2J,K), which was 
confirmed by proteoglycan content loss (Figure 2L). These mor-
phological changes were reduced in ST2−/− mice (Figures 2I–K). 
Further, WT mice presented increased mRNA expression of 
receptor activator of nuclear factor-kappa B ligand (Figure S1A 
in Supplementary Material) and receptor activator of nuclear 
factor-kappa B (Figure S1B in Supplementary Material), and 
reduced mRNA expression of OPG (osteoprotegerin, Figure 
S1C in Supplementary Material), an expression pattern indicat-
ing bone resorption (42). These results indicate that IL-33/ST2 
signaling deficiency ameliorated the clinical features of septic 
arthritis. Therefore, we next examined whether the reduction 
of disease intensity in ST2−/− mice would be related to reducing 
FigUre 3 | ST2 deficiency enhances neutrophil and macrophages bactericidal activity against Staphylococcus aureus. S. aureus was injected in the femur-tibial 
joint of wild-type (WT) and ST2−/− mice. At indicated points (7–28 days post-infection), (a) knee joints and (B) spleen samples were collected and bacterial counts 
were determined on agar dishes. (c,D) FACS analysis of neutrophils (1 × 106) from WT and ST2−/− naïve mice incubated in vitro with S. aureus  
at a multiplicity of infection (MOI) of 3 to evaluate phagocytosis. (e,F) FACS analysis of naïve bone marrow-derived macrophages (BMDMs) (1 × 106) from WT and 
ST2−/− naïve mice incubated in vitro with S. aureus at a MOI of 3 to evaluate phagocytosis. Microbicidal activity of neutrophils (g) and BMDM (h) from WT and 
ST2−/− naïve mice preincubated with interferon-γ (IFN-γ) (100 IU/ml, 1 h) against S. aureus. All neutrophils were harvested from the bone marrow of mice. N = 6 
wells per group per in vitro experiment, representative of two independent experiments. One-way ANOVA followed by Tukey’s test. #P < 0.05 vs WT mice group 
(a,B). Samples were pooled from 10 mice per group per in vitro experiment, representative of two independent experiments. One-way ANOVA followed by Tukey’s 
test. #P < 0.05 vs WT neutrophils or BMDM group (c–F). *P < 0.05 vs WT group preincubated with only medium (g,h).
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inflammation since IL-33/ST2 signaling triggers inflammatory 
responses, or if ST2 deficiency would enhance the anti-microbial 
response due to boosting the immune response pattern necessary 
to combat S. aureus infection.
sT2 Deficiency enhances neutrophil and 
Macrophages Bactericidal activity against 
S. aureus
Inhibiting IL-33/ST2 signaling reduces inflammation induced by 
carrageenan and LPS, and in RA by targeting neutrophilic influx 
(14, 41, 43, 44). On the other hand, neutrophils have a fundamental 
role in controlling the bacterial load in infections. Indeed, the 
treatment with IL-33 improves the sepsis outcome due to inhibi-
tion of LPS-induced CXCR2 internalization, which maintains the 
neutrophil migration toward the infectious foci (19). To ascertain 
this issue and considering that mice lacking ST2 showed a protec-
tive phenotype against S. aureus local inflammation in septic 
arthritis (Figure 2), first, we evaluated if there was any difference 
in the bacterial load in WT and ST2−/− mice. Bacterial recovery 
showed that WT mice presented detectable S. aureus CFU in both 
the knee joint and the spleen (Figures 3A,B, respectively). On the 
other hand, ST2−/− mice presented reduced CFU number compared 
with WT mice as well as did not present S. aureus in the spleen, 
which indicates that the infection remained local in ST2−/−, but not 
in WT mice (Figure 3B). Given neutrophils and macrophages are 
the initial defenders against S. aureus infection (45), we determined 
if ST2 deficiency would influence neutrophil and macrophage 
phagocytosis and killing of S. aureus. Using FITC-labeled S. aureus, 
we found that both neutrophils (Figures 3C,D) and macrophages 
(BMDMs) (Figures  3E,F) from WT mice presented reduced 
phagocytic capacity when compared with ST2−/− cells. In addition, 
neutrophils and BMDMs from WT mice also partially controlled 
bacterial growth, and, importantly, neutrophils and BMDMs from 
WT mice increased their bacterial killing after stimulation with 
recombinant IFN-γ (Figures  3G,H) in a manner that reached 
the capability of ST2−/− cells. In contrast, the IFN-γ treatment 
of neutrophils and BMDMs from ST2−/− mice did not further 
enhanced their bactericidal effect (Figures 3G,H), possibly because 
this pathway was already being enhanced by ST2 deficiency. Thus, 
these results show that impaired endogenous IL-33/ST2 signaling 
enhances neutrophil and macrophage bacterial killing with a profile 
that can be matched by IFN-γ treatment. Therefore, IFN-γ-related 
mechanisms were investigated in the following experiments (46).
FigUre 4 | ST2 deficiency enhances NO production by neutrophils and macrophages and reduces Staphylococcus aureus-induced septic arthritis. NO production 
was determined as nitrite concentration by Griess reagent in the culture supernatant of (a) neutrophils and (B) bone marrow-derived macrophages (BMDMs) cells 
from wild-type (WT) or ST2 −/− naïve mice preincubated in vitro with interferon-γ (IFN-γ) (100 IU/ml, 1 h) or medium, followed by incubation with S. aureus, or (c) in 
the culture supernatant of macrophages like-cells isolated from peritoneal cavity of WT or ST2−/− mice with staphylococcal arthritis and challenged with lipoteichoic 
acid (LTA) (10 µg/ml, a toll-like receptor 2 agonist) plus IFN-γ (100 UI/ml) for 48 h. S. aureus or saline (day 0) was injected in the femur-tibial joint of WT and ST2−/− mice 
and knee joint samples were collected and processed to determine: (D) the mRNA and (e) protein expression of iNOS at indicated time points post-infection by qPCR 
and Western Blot, respectively. WT and ST2−/− mice were treated with aminoguanidine (AMG, 30 mg/kg, s.c., 150 µl) or vehicle (saline, 150 µl) over 28 days after i.a. 
S. aureus [107 colony-forming unity (CFU)/10 μl/joint] injection: (F) mechanical hyperalgesia, (g) articular edema, and (h) clinical severity score were evaluated over 
27 days post-bacterial infection. At the 28th day post-infection, (i) leukocyte recruitment to the articular cavity, (J) bacterial counts in knee joint cavity and 
(K) spleen, and (l) proteoglycan content in patella samples were determined. N = 6 per group per in vivo experiment or N = 4 per group for WB analysis and 
samples were pooled from 10 mice per in vitro experiment. *P < 0.05 vs WT neutrophils or BMDM group preincubated with only medium, or vs mice naïve group; 
#P < 0.05 vs WT and ST2−/− neutrophils or BMDM group preincubated with only medium, or vs WT mice group (a–e). *P < 0.05 vs naïve mice group; #P < 0.05 vs 
ST2−/− + saline mice group vs WT + saline mice group; **P < 0.05 WT + AMG mice group vs WT + saline mice group; ##P < 0.05 ST2−/− + AMG mice group vs 
ST2−/− + saline mice group (F–l). Representative of two independent experiments. One-way ANOVA followed by Tukey’s test.
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sT2 Deficiency enhances nO Production 
by neutrophils and Macrophages and 
reduces S. aureus-induced septic 
arthritis
Since one of the IFN-γ mechanisms of bacterial killing is by 
increasing NO production in an iNOS-dependent manner 
(47) and that NO can also drive type 1 response (48–50), it was 
evaluated whether the protective phenotype of ST2 deficiency 
was related to an increase of IFN-γ/iNOS/NO signaling. First, it 
was measured the NO2− levels in macrophages and neutrophils, 
which is indicative of iNOS activity. We found that neutrophils 
from WT mice presented lower production of NO2− than neutro-
phils from ST2−/− mice (Figure 4A) as well as IFN-γ enhanced 
the NO2− production by WT neutrophils, but not ST2−/− neutro-
phils. In accordance, naïve macrophages (BMDMs) infected with 
S. aureus or peritoneal macrophages collected at 7–28 days post 
S. aureus joint infection from WT presented reduced levels 
of NO2− when compared with ST2−/− cells (Figures  4B,C, 
respectively). Considering neutrophils and macrophages 
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from WT mice presented reduced NO2− levels compared with 
ST2−/− cells, the iNOS expression was investigated in knee joint 
samples from WT and ST2−/− mice with staphylococcal arthritis. 
Corroborating, both iNOS mRNA expression and protein (day 
21, peak of mRNA expression) were reduced in the knee joints 
from WT mice compared with ST2−/− mice (Figures  4D,E, 
respectively). Thus, to determine the contribution of iNOS to 
IL-33/ST2 signaling role in septic arthritis, WT and ST2−/−mice 
with septic arthritis received daily treatment with AMG, a selec-
tive iNOS inhibitor. Treatment with AMG reverted the protective 
effect of ST2 deficiency and also worsened the phenotype of WT 
mice, as observed by increased hyperalgesia (reduced mechani-
cal threshold, Figure  4F), edema (Figure  4G), and clinical 
score (Figure 4H), when compared with the group that receive 
only vehicle. Similarly, the treatment with AMG in ST2−/− mice 
increased leukocyte recruitment to the knee joint (Figure  4I), 
CFU count in both knee joint (Figure 4J) and spleen (Figure 4K), 
and proteoglycan degradation (Figure 4L) at the 28th day post-
infection (Figures 4I–L). Altogether, these data indicate that ST2 
receptor deficiency ameliorates S. aureus-induced septic arthritis 
by enhancing iNOS expression and thereby increasing NO levels, 
which is an important bactericidal mechanism and inductor of 
type 1 response.
sT2 Deficiency enhances Type 1-Driven 
immune response against S. aureus in 
septic arthritis
Proper Th1 response alongside with antibiotic therapy is funda-
mental to kill S. aureus (47, 51). Previous evidence shows that 
IL-33/ST2 signaling favors the expansion of type 2 cells; how-
ever, there is also evidence that IL-33 enhances type 1 immune 
responses (1, 4). Thus, to further address the mechanism underly-
ing the outcome of ST2 deficiency in septic arthritis, it was next 
performed a flow cytometry gating CD4+IFN-γ+T  cells and 
CD4+IL-4+T cells at the 7th and 14th day post-infection in LNs 
cells. These time points were chosen based on ST2−/−phenotype 
observed during septic arthritis and on the fact that CFU count 
in the joint was higher at the 7th and 14th day post-infection. 
Flow cytometry data show that ST2 expression was essential to 
the development of a Th2 response in septic arthritis (Figures 
S2A,B in Supplementary Material). We showed that ST2−/− mice 
had higher number of gated CD4+IFN-γ+T cells than WT mice 
at days 7 and 14 post-infection (Figures  5A,B). In contrast, 
the S. aureus induced an increase of the percentage of gated 
CD4 +  IL-4 +  T  cells at days 7 and 14 post-infection in WT 
mice, which was reduced by ST2 deficiency (Figures S2A,B in 
Supplementary Material). In line with FACS data, WT mice 
presented reduced amounts of IFN-γ and increased amounts 
of IL-4 in infected joints, which are opposed results compared 
to ST2−/− at all time points evaluated (7–28 days post-infection, 
Figure 5C; Figure S2C in Supplementary Material). This suggests 
that endogenous IL-33 is essential to driving type 2 response in 
septic arthritis which are mediated by IL-4. This axis favored the 
infection progression by counteracting type 1 response. In view of 
Th1 and Th2 response have long been balancing one another (52) 
and that there are similar evidences regarding the relationship 
between Th1 and Th17 (52, 53), we found a lower number of gated 
IL-17+CD4+T cells in LNs from ST2−/− mice compared with WT at 
7th and 14th day post-infection (Figures S2D,E in Supplementary 
Material), which lined up with IL-17 amounts in infected joint 
tissue at all time points evaluated (7–28  days post-infection, 
Figure S2F in Supplementary Material), raising the possibility 
that ST2−/− mice use Th1 cells in lieu of Th17 cells to drive the 
immune response against S. aureus-induced septic arthritis. We 
also found that WT mice presented increased number of CD4+ 
IL-10+ T cells in LNs when compared with ST2−/− mice at the 7th 
day post-infection (Figures S2G,H in Supplementary Material). 
This high IL-10 production in the beginning of infection in WT 
mice possibly favored bacterial growth (54). At the 14th day post-
infection, there was a decrease switch in the number of CD4+ 
IL-10+T+ cells observed in WT and ST2−/− mice with an increase 
in ST2−/− mice (Figures S2G,H in Supplementary Material) 
and it lined up with the IL-10 amounts in infected joints at all 
times points evaluated (7–28 days post-infection, Figure S2I in 
Supplementary Material). Thus, increasing CD4+IL-10+T+ cells 
and IL-10 production at later time points in the course of septic 
arthritis at which the infection was already controlled could be a 
mechanism to reduce joint inflammation in ST2−/− mice.
M1 macrophage polarization can be driven by microbial 
infection and secondarily drive the T helper (Th1) polarization 
under influence of IFN-γ. We observed that S. aureus induced the 
mRNA expression of IL-33 (Figure 5D) and ST2 (Figure 5E) as 
well as IL-33 (Figure 5F) production by BMDM. Therefore, the 
infectious agent induces IL-33 production, which is in line with 
an altered response in the absence of IL-33 receptor, ST2. IFN-γ 
is crucial for NO production and evidence demonstrates that 
BMDM produce IFN-γ and NO in response to L. amazonensis 
(55). In this sense, we found that S. aureus-induced IFN-γ mRNA 
(Figure  5G) and protein (Figure  5H) only in ST2−/− BMDM, 
but not in WT BMDM. This result explains why adding IFN-γ 
to the media could not increase the microbicide activity of 
ST2−/− BMDM (Figure 4B) and suggests that the effect of ST2 
deficiency depends on inducing IFN-γ in BMDM in addition to 
increasing Th1 cell skewing. Corroborating this conclusion, anti-
IFN-γ antibody treatment inhibited the enhanced iNOS mRNA 
expression (Figure 5I), iNOS levels (Figure 5J), NO2− production 
(Figure 5K), and bacterial killing (Figure 5L) of ST2−/− BMDMs 
compared with WT BMDMs in response to S. aureus. These 
results confirm that the protection against S. aureus conferred by 
ST2 deficiency depends on inducing IFN-γ production. It is likely 
that S. aureus stimulus induces IL-33 that acting via ST2 limits 
IFN-γ production by BMDM functioning as an endogenous 
regulator of anti-bacterial mechanisms, and upon ST2 deficiency, 
IFN-γ can be produced to unleash the full microbicide activity 
of BMDMs.
iFn-γ contributes to the resolution 
of staphylococcal arthritis
Considering the importance of IFN-γ in the bacterial clearance 
and that ST2 deficiency enhances IFN-γ+CD4+T  cells skewing 
and IFN-γ-dependent killing activity of BMDM, it was then 
investigated whether mice lacking IFN-γ presented impaired 
FigUre 5 | ST2 deficiency enhances type 1-driven immune response against Staphylococcus aureus in septic arthritis S. aureus or saline was injected in in the 
femur-tibial joint of wild-type (WT) and ST2−/− mice. (a) Representative FACS plots and (B) the percentage of interferon-γ (IFN-γ)-producing CD4+T cells 
(CD4+IFNγ+T cells) from lymph node collected at day 7 and 14 post-infection and evaluated by flow cytometry, and (c) IFN-γ concentrations in the knee joints of WT 
and ST2−/− at 7–28 days post-infection determined by ELISA. bone marrow-derived macrophages (BMDMs) (1 × 106) from naïve WT mice were incubated in vitro 
with S. aureus at a multiplicity of infection (MOI) of 3 for 18 h to assess: (D) interleukin-33 (IL-33) mRNA and (e) ST2 mRNA expression by qPCR, (F) IL-33 levels by 
ELISA. BMDMs (1 × 106) from naïve WT and ST2−/− mice incubated in vitro with S. aureus at a MOI of 3 for 18 h to assess: (g) IFN-γ mRNA expression by qPCR 
and (h) IFN-γ levels by ELISA. BMDMs from naïve WT and ST2−/− mice preincubated 1 h in vitro with IFN-γ (100 IU/ml), anti-IFN-γ (10 µg/ml) or medium, followed by 
incubation with S. aureus at a MOI of 3 for 18 h to assess: (i) iNOS mRNA expression by qPCR, (J) iNOS protein expression by Western Blot, and (K) NO 
production determined as nitrite concentration by Griess reagent in the culture supernatant. (l) BMDMs (1 × 106) from naïve WT and ST2−/− mice preincubated 1 h 
in vitro with IFN-γ (100 IU/ml), anti-IFN-γ (10 µg/ml), or medium, followed by incubation with S. aureus at a MOI of 3 for 3 h to assess bactericidal capability of 
BMDMs by Killing assay. N = 5 per group per in vivo experiment. *P < 0.05 vs WT naïve group (B) or vs day 0 of infection (c), #P < 0.05 vs WT mice group (B,c). 
Representative of two independent experiments. One-way ANOVA followed by Tukey’s test. For in vitro experiments: Samples were pooled from 5 mice per group, 
N 5 wells per group per in vitro experiment. *P < 0.05 vs WT medium group (D–F, K) or only bacteria group (l). #P < 0.05 vs WT S. aureus group (g–i) or vs WT 
medium (l), ##P < 0.05 vs WT IFN-γ + S. aureus group and WT S. aureus group (i,K), **P < 0.05 vs ST2−/− S. aureus group and WT IFN-γ + S. aureus group (i–K), 
fP < 0.05 vs ST2−/− S. aureus group (i–l). Representative of two independent experiments. One-way ANOVA followed by Tukey’s test.
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response in septic arthritis and whether this was related to IL-33 
production. Mice lacking IFN-γ presented increased mechani-
cal hyperalgesia and edema in all disease course (Figures 6A,B, 
respectively). The differences in clinical features were more 
prominent from day 13 post-infection as observed by an increase 
in clinical score in IFN-γ−/− when compared with WT mice 
(Figure 6C). IFN-γ−/− mice presented increased leukocyte recruit-
ment inflammatory cell infiltrate with predominance of polymor-
phonuclear leukocytes over mononuclear cells (Figures 6D–F), 
remarkable cartilage destruction, and architecture as confirmed 
by proteoglycan content loss and histopathology (Figures 6F–H). 
The septic arthritis development pattern was thoroughly different 
comparing WT and IFN-γ−/− mice as observed by the knee joint 
edema and clinical score (Figures 6B,C). In fact, a lower bacterial 
killing was observed resulting in higher CFU counts in the joint and 
spleen of IFN-γ−/− mice compared with WT mice (Figures 6I,J). 
Ultimately, this profile observed in IFN-γ−/− mice was related to 
higher IL-33 production, and lower sST2 levels than WT mice 
(Figures 6K,L). All the parameters were observed up to or in the 
28th day post-infection (Figure 6). Importantly, the same dose of 
S. aureus was used in WT C57BL/6 and WT Balb/c mice to induce 
septic arthritis. Both mouse strains were susceptible to infection; 
FigUre 6 | Interferon-γ (IFN-γ) contributes to the resolution of staphylococcal arthritis. Staphylococcus aureus or saline was injected in in the femur-tibial joint of 
wild-type (WT) and IFN-γ−/− mice. (a) Mechanical hyperalgesia, (B) articular edema, and (c) clinical score were evaluated over 27 days post-infection. At 28-day 
post-infection, knee joint samples were collected at 28-day post-infection to determine: (D) leukocyte recruitment to the articular cavity, histopathological analysis  
of hematoxylin/eosin stained slices: (e) representative images of knee joints at 28 post-infection in original magnification ×10. The letter a indicates a heavily 
inflamed joint with cartilage destruction and pannus formation, (F) synovitis score (intensity: 1–4), and (g) cartilage destruction score (intensity: 1–4). At 28-day 
post-infection, (h) proteoglycan content in patellas, (i) bacterial counts in knee joint cavity, (J) and were determined, and (K) interleukin-33 (IL-33) and (l) sST2 
concentrations in knee joints were determined by ELISA. Correlation analysis of IL-33 and IFN-γ levels determined by ELISA in synovial fluid samples from patients 
with septic arthritis. For inflammatory parameters and proteoglycan content: n = 6 per group per in vivo experiment, representative of two independent experiments. 
*P < 0.05 vs naïve mice group, #P < 0.05 vs WT mice group (a–D,h–l). One-way ANOVA followed by Tukey’s test. For histological analysis: n = 8 per group per 
experiment, representative of two independent experiments. *P < 0.05 vs naïve mice group, #P < 0.05 vs WT mice group (e–g). Kruskal–Wallis test followed by 
Dunn’s test. Spearman rank correlation test was used for the assessment of correlation (M). Abbreviations: C, cartilage; JC, joint cavity.
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however, there was a clear difference in the disease intensity. The 
C57BL/6 mouse with pronounced type 1 and type 3 immune 
responses presented lessened disease severity that allowed 
observing the disease exacerbation in IFN-γ−/− mouse (Figure 6). 
The WT Balb/c with a more prominent type 2 profile could not 
inhibit bacterial growth. The ST2 deficiency enhanced the type 1 
immune response resembling the WT C57BL/6 profile, indicate 
that IFN-γ deficiency impairs the immune response against S. 
aureus-induced septic arthritis similarly to Balb/c mice expressing 
ST2, which lines up with the data showing that IFN-γ deficiency 
increased IL-33 production. Thus, enhancing IFN-γ is an essential 
mechanism to solve septic arthritis and can be achieved by ST2 
deficiency. Finally, we quantitated IFN-γ in synovial fluid samples 
of patients with septic arthritis and compared with the IL-33 
levels observed in Figure  1A. An inverse relationship between 
the levels of IL-33 and IFN-γ was observed (Figure  6M and 
Figure S3 in Supplementary Material). Making a parallel of the 
data presented in this manuscript and Figure  6M, we would 
suggest that with higher levels of IL-33, lower levels of IFN-γ will 
be observed in the synovial fluid of septic arthritis patients, and 
changing the balance of this relationship may interfere with the 
disease outcome.
DiscUssiOn
The present study demonstrates that the IL-33 receptor, ST2, con-
tributes to the development of S. aureus-induced septic arthritis. 
This contribution is drastic in a manner that ST2 deficiency 
resulted in a better disease outcome. ST2 deficiency increased 
the Th1 skewing and induced IFN-γ production by BMDM that 
presented a boosted response with enhanced bacteria killing via 
NO. Septic arthritis presents severe and permanent joint sequelae 
(29, 31), and the present data suggests that ST2 deficiency amelio-
rates this infections disease.
The knees are the most common joints that are affected in septic 
arthritis in humans (27). The diagnosis of septic arthritis depends 
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on isolating the pathogen from aspirated synovial fluid from knee 
joints (29, 56). We observed that patients have significantly more 
IL-33 and no detectable concentrations of sST2 in their synovial 
fluid compared those of the osteoarthritis patients. In the mouse 
model of septic arthritis, substantial amounts of IL-33 as well as 
markedly reduced sST2 levels were observed in the knee joint. 
Thus, the mouse septic arthritis model replicates this IL-33/
sST2 balance observed in septic arthritis patients. These clinical 
and experimental findings are consistent with the notion that 
the IL-33 levels are tightly regulated by sST2 availability (1, 4, 
11, 57), suggesting that during S. aureus septic arthritis there is an 
enhanced availability and, potentially, activity of IL-33.
Infectious disease is the outcome of an intense crosstalk 
between invading pathogen and host defense armory (58). In 
septic arthritis, the synovial membrane inflammation leads to 
tissue destruction and dysfunction, resulting into significant 
painful condition and morbidity (28, 56, 59). In this context, the 
effect of ST2 deficiency in staphylococcal arthritis was evident 
since the first day after bacteria injection, inducing articular 
hyperalgesia, edema and a focal collection of immune cells that 
secret proinflammatory mediators such as TNF-α and IL-1β, 
which in turn contribute to the knee joint lesion, abscess and 
function loss (28). Indeed, IL-33 can orchestrate the influx of 
neutrophils and other immune cells subsidizing a dysfunctional 
joint inflammation in other arthritis models (13–15, 60). 
Conversely, using ST2 deficient mice, we observed a decrease in 
articular hyperalgesia, clinical score, and all inflammatory profile 
of staphylococcal arthritis over 28 days as result of a better control 
of infection, establishing a relationship between ST2 deficiency 
and intrinsic factors modulating microbicide mechanisms. The 
initial phenotype results could represent a reduction of inflam-
matory response since IL-33 induces hyperalgesia and edema 
(13, 41). Reduced inflammation would result in diminished 
killing of bacteria, which would be in line with evidence that in 
ovalbumin-induced airway inflammation IL-33 does not affect 
NO production from iNOS (61). However, this was not true in 
the present experimental condition since ST2 deficiency resulted 
in a better killing activity and control of staphylococcal arthritis 
avoiding the infection to become systemic. The ST2 deficiency 
allowed an enhancement of a Th1 cells activation of neutrophils 
and macrophages with IFN-γ with enhanced anti-bacterial activ-
ity. Unexpectedly, ST2 deficient macrophages produced IFN-γ for 
an autocrine induction of iNOS expression/NO production and 
killing activity, thus, suggesting that ST2 deficiency also favors an 
M1 macrophage phenotype that contributes to protect the host 
against S. aureus infection. Corroborating these data, an essential 
role for NO and other NO congeners in controlling septic arthritis 
was demonstrated (28, 62).
Extrapolating to others bacterial infections, IL-33/ST2 axis has 
apparent pleiotropic functions shaped by the local microenviron-
ment (4, 19, 21, 38, 63, 64). Our findings appear to contradict the 
reports showing the beneficial role of IL-33 on bacterial infec-
tions, including cutaneous S. aureus infection (21, 63, 64). One 
fundamental explanation is that even before the recognition of 
IL-33, it was demonstrated that ST2 makes a negative-feedback 
control of IL-1RI and TLR signaling via sequestration of MyD88 
and Mal through TIR domain (3, 65). Direct activation of TLRs 
in neutrophils, specifically TLR2 in staphylococcal infections, 
downregulates the expression of chemokine receptor CXCR2 that 
keeps their recruitment to infectious foci. Thus, once at infectious 
focus, neutrophils no longer need to continue migrating, but they 
must solve the infection by producing microbicide molecules such 
as NO (19, 66). Further, NO produced from iNOS also down-
regulates chemokine receptor expression (19,  67). Considering 
that IL-33 interferes with TLR signaling (19), it is reasonable to 
suppose that in ST2−/− mice with septic arthritis, TLR2 signaling 
will be boosted allowing neutrophils and macrophages to produce 
larger amounts of NO via iNOS to eliminate the bacteria. This 
signaling also links innate and Th1-biased adaptive response (65). 
Moreover, acute sepsis also presents differences with septic arthri-
tis that contribute to understand the pleiotropic roles of IL-33. 
Acute sepsis is dependent on innate immune responses, although 
it triggers immune suppression in the patients that survive (38). 
On the other hand, septic arthritis is a disease with extremely 
aggressive acute effects, but also with a chronic temporal profile 
that allows the development of adaptive immune response as 
observed here in. The present data supports that ST2 deficiency 
will allow the development of Th1 adaptive immune response and 
a better control of infection via enhanced IFN-γ production and 
consequent increase microbicide activity of phagocytes.
NO has a selective enhancing effect on the induction and dif-
ferentiation of Th1 but not Th2 cells (49, 68, 69). Th1 cells in a 
feedback loop amplify NO synthesis further via activation of M1 
macrophages by IFN-γ and suppress IL-4 synthesis, leading to 
the production of large amounts of NO that is essential for killing 
pathogens (68). Importantly, a strong Th1 response is desirable for 
effective host defense against S. aureus (63). Conversely, a skew-
ing toward a type 2 immune response is thought to contribute to 
impaired immune defenses in S. aureus-induced septic arthritis 
(70). Consistent with the inability of WT mice in controlling the 
infection, these mice showed Th2 profile in septic arthritis with 
high-IL-4/CD4+T  cell and low-IFN-γ/CD4+T  cell counts. In 
the absence of ST2, the polarization of lymphocytes and type 2 
cytokines production was abolished allowing the skewing toward 
Th1 phenotype. The ST2 deficiency also inhibited Th17 expansion 
and promoted IL-10 production. These data are in agreement that 
IFN-γ production might overlap IL-17 release in septic arthritis 
(71) and that IL-10 was released in order to achieve a state of 
tissue homeostasis in chronic phase of septic arthritis (72).
Concluding, we find a novel endogenous role for the IL-33 
receptor, ST2, in septic arthritis. Abrogating ST2 expression 
enhances the Th0 polarization toward a Th1 phenotype that via 
IFN-γ induces iNOS-derived NO production by macrophages 
and neutrophils improving the killing activity of these innate 
immune cells. Furthermore, ST2 deficient macrophages produce 
IFN-γ that boosts their bactericide armory. Therefore, ST2 defi-
ciency is beneficial in S. aureus-induced septic arthritis.
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